🧪
hypothesis

TREM2-APOE microglial state switching across AD, ALS, and PD

Hypothesis

TREM2-APOE microglial state switching across AD, ALS, and PD

Shared mechanism across AD, ALS, PD: TREM2-APOE signaling shifts microglia into a disease-associated state that can clear debris but also amplify inflammatory injury.
🧬 TREM2🩺 multi🎯 Composite 80%💱 $0.53▲2.9%validated
neurodegeneration
EvidenceStrong (88%)📖 14 cit🗣 1 debates✓ 3 support✗ 1 oppose
⚠ Low Validation Senate Quality Gates →
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite80%

🧪 Overview

Shared mechanism across AD, ALS, PD: TREM2-APOE signaling shifts microglia into a disease-associated state that can clear debris but also amplify inflammatory injury. AD genetics implicate TREM2; ALS data connect TREM2 to TDP-43 neuroprotection; and PD microglia share the same damage-response programs around alpha-synuclein stress.

Falsifiable prediction: A biased TREM2 agonist that enhances phagocytosis without excessive NF-kB/AP-1 activation should improve aggregate clearance in AD amyloid, TDP-43 ALS, and alpha-synuclein PD cultures while reducing IL1B/TNFA induction by at least 20%.

Proposed experiment: Differentiate isogenic human microglia with TREM2 knockout, rescue, and biased agonist treatment; co-culture with amyloid/tau, TDP-43, and alpha-synuclein neuron models; assay phagocytosis, APOE-state markers, cytokines, complement deposition, and neuronal survival.

Cross-disease confidence rationale: Human AD genetics plus ALS TDP-43 microglial neuroprotection and broad DAM literature.

Internal SciDEX support: SciDEX support query found 313 matching hypotheses across 8 disease labels, including 313 with debate_count > 0.

...

🧬 Mechanism

🔗 Mechanism from KG for TREM2

Auto-built from this analysis's top knowledge-graph edges.

graph TD
    TREM2_R47H_variant["TREM2 R47H variant"] -->|increases risk| Ad["Ad"]
    TREM2["TREM2"] -->|cross disease mech| AD["AD"]
    TREM2_1["TREM2"] -->|cross disease mech| ALS["ALS"]
    TREM2_2["TREM2"] -->|cross disease mech| PD["PD"]
    h_cross_synth_trem2_apoe_["h-cross-synth-trem2-apoe-microglia"] -->|proposes shared me| TREM2_3["TREM2"]
    style TREM2_R47H_variant fill:#ce93d8,stroke:#333,color:#000
    style Ad fill:#ef5350,stroke:#333,color:#000
    style TREM2 fill:#4fc3f7,stroke:#333,color:#000
    style AD fill:#ef5350,stroke:#333,color:#000
    style TREM2_1 fill:#4fc3f7,stroke:#333,color:#000
    style ALS fill:#ef5350,stroke:#333,color:#000
    style TREM2_2 fill:#4fc3f7,stroke:#333,color:#000
    style PD fill:#ef5350,stroke:#333,color:#000
    style h_cross_synth_trem2_apoe_ fill:#4fc3f7,stroke:#333,color:#000
    style TREM2_3 fill:#4fc3f7,stroke:#333,color:#000

⚖️ Evidence

⚖️ Evidence Matrix3 supports0 contradicts
Supports
TREM2 variants are associated with Alzheimer's disease.
2013PMID:23150934high
Supports
The TREM2-APOE pathway drives dysfunctional microglial phenotype in neurodegeneration.
2017PMID:28930663high
Supports
TREM2 interacts with TDP-43 and mediates microglial neuroprotection.
2022PMID:34916658high
📖 Linked Papers (3)Export BibTeX ↗
TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration.
Nature neuroscience (2022) · PubMed:34916658 ↗
17 figures
Extended Data Fig. 1
Extended Data Fig. 1
Characterizations of GFP-hTDP-43 expression in a neonatal TDP-43 mouse model. GFP-hTDP-43 expression was induced via intracerebroventricular injection of AAV9.C...
Extended Data Fig. 2
Extended Data Fig. 2
Characterizations of motor deficits and neuronal loss in a neonatal TDP-43 mouse model. GFP-hTDP-43 expression was induced via intracerebroventricular injection...
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.
Immunity (2017) · PubMed:28930663 ↗
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
TREM2 variants in Alzheimer's disease.
The New England journal of medicine (2013) · PubMed:23150934 ↗
No figures

🏥 Translation

🧬 3D Protein Structure — TREM2

🧬 PDB 6YXY Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for TREM2 →

No DepMap CRISPR Chronos data found for TREM2.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0005
Events (7d)
1
Price History
▲2.9%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

🔮 Predictions

🔎 Predictions vs Observations1 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
A biased TREM2 agonist that enhances phagocytosis without excessive NF-kB/AP-1 activation should improve aggregate clearance in AD amyloid, TDP-43 ALS, and alpha-synuclein PD cultures while reducing IIf this mechanism is real, then A biased TREM2 agonist that enhances phagocytosis without excessive NF-kB/AP-1 activation should improve aggregate clearance in — no observation —pending0.80
🔮 Falsifiable Predictions (1)
pendingconf 80%
A biased TREM2 agonist that enhances phagocytosis without excessive NF-kB/AP-1 activation should improve aggregate clearance in AD amyloid, TDP-43 ALS, and alpha-synuclein PD cultures while reducing IL1B/TNFA induction by at least 20%.
Predicted outcome: If this mechanism is real, then A biased TREM2 agonist that enhances phagocytosis without excessive NF-kB/AP-1 activation should improve aggregate cle
Falsification: Falsified if the experiment produces results more than 20% below the predicted effect size
View on SciDEX ↗